IMPACT BIOMEDICAL INC.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
IBO$4.62+6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| 2024 | 2023 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(24,770,000) | $(4,407,000) |
| Adjustments to reconcile net loss to net cash used by operating activities: | ||
| Depreciation and amortization | 1,119,000 | 1,120,000 |
| Stock based compensation | 19,000 | - |
| Change in fair value of note payable, related party | (5,068,000) | - |
| Change in deferred tax liability | 33,000 | - |
| Impairment of fixed assets | 263,000 | - |
| Impairment of goodwill | 25,093,000 | |
| Decrease (increase) in assets: | ||
| Other receivable | 128,000 | (128,000) |
| Prepaid expenses and other current assets | (265,000) | 104,000 |
| Increase (decrease) in liabilities: | ||
| Accounts payable | (436,000) | 293,000 |
| Accrued expenses | (35,000) | 167,000 |
| Net cash used by operating activities | (3,919,000) | (2,851,000) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | - | (18,000) |
| Payments received on notes receivable | 2,000 | 3,000 |
| Net cash provided (used) by investing activities | 2,000 | (15,000) |
| Cash flows from financing activities: | ||
| Borrowings from revolving lines of credit, net | 2,189,000 | 2,865,000 |
| Issuances of common stock, net of issuance costs | 3,726,000 | - |
| Net cash provided by financing activities | 5,915,000 | 2,865,000 |
| Net increase (decrease) in cash | 1,998,000 | (1,000) |
| Cash and cash equivalents at beginning of year | 1,000 | 2,000 |
| Cash and cash equivalents at end of year | $1,999,000 | $1,000 |
**I
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.